AllianzGI Diversified Income & (ACV) Trades at $22.95 After Triangle; Surmodics Has 0.69 Sentiment

Surmodics, Inc. (NASDAQ:SRDX) Logo

AllianzGI Diversified Income & (ACV) formed triangle with $21.34 target or 7.00% below today’s $22.95 share price. AllianzGI Diversified Income & (ACV) has $ valuation. The stock increased 0.42% or $0.1 during the last trading session, reaching $22.95. About 35,766 shares traded or 12.47% up from the average. AllianzGI Diversified Income & (NYSE:ACV) has risen 14.12% since May 11, 2017 and is uptrending. It has outperformed by 2.57% the S&P500.

Surmodics Inc (SRDX) investors sentiment decreased to 0.69 in 2017 Q4. It’s down -0.25, from 0.94 in 2017Q3. The ratio has worsened, as 38 active investment managers increased or opened new equity positions, while 55 reduced and sold their positions in Surmodics Inc. The active investment managers in our database now have: 11.07 million shares, down from 11.18 million shares in 2017Q3. Also, the number of active investment managers holding Surmodics Inc in top ten equity positions was flat from 1 to 1 for the same number . Sold All: 11 Reduced: 44 Increased: 26 New Position: 12.

More important recent Surmodics, Inc. (NASDAQ:SRDX) news were published by: Seekingalpha.com which released: “FDA clears Surmodic’ low-profile catheter” on April 23, 2018, also Benzinga.com published article titled: “Benzinga’s Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway”, Nasdaq.com published: “Detailed Research: Economic Perspectives on Vitamin Shoppe, Surmodics, Spark Therapeutics, QUANTENNA …” on May 01, 2018. More interesting news about Surmodics, Inc. (NASDAQ:SRDX) was released by: Businesswire.com and their article: “Surmodics to Webcast Second Quarter Fiscal 2018 Earnings Conference Call on May 2” with publication date: April 24, 2018.

Surmodics, Inc., together with its subsidiaries, provides surface modification and in vitro diagnostic technologies to the healthcare industry worldwide. The company has market cap of $593.96 million. It operates through two divisions, Medical Device and In Vitro Diagnostics. It has a 22400 P/E ratio. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets.

Since January 1, 0001, it had 0 buys, and 2 sales for $63,711 activity.

The stock increased 2.52% or $1.1 during the last trading session, reaching $44.8. About 54,061 shares traded or 7.79% up from the average. Surmodics, Inc. (SRDX) has risen 61.37% since May 11, 2017 and is uptrending. It has outperformed by 49.82% the S&P500.

Trigran Investments Inc. holds 8.22% of its portfolio in Surmodics, Inc. for 1.31 million shares. Murphy Pohlad Asset Management Llc owns 63,900 shares or 1.18% of their US portfolio. Moreover, Teton Advisors Inc. has 0.71% invested in the company for 276,792 shares. The California-based Menta Capital Llc has invested 0.29% in the stock. Rice Hall James & Associates Llc, a California-based fund reported 104,386 shares.

Surmodics, Inc. (NASDAQ:SRDX) Institutional Positions Chart